Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease

Documenti analoghi

• Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia
  di: Claassen Daniel O. MD, et al.
  Pubblicazione: (2023-10-01)
• Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia
  di: Frank S, et al.
  Pubblicazione: (2023-12-01)
• Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
  di: Samuel Frank, et al.
  Pubblicazione: (2024-09-01)
• Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington’s disease chorea based on network meta-analysis
  di: Jing Huang, et al.
  Pubblicazione: (2025-09-01)
• TARDIVE DYSTONIA, TARDIVE DYSKINESIA AND TREATMENT APPROACHES
  di: Cenk Özdemir, et al.
  Pubblicazione: (2021-03-01)